Epithelioid Mesothelioma
Pathology, symptoms, diagnosis, treatment and prognosis
Epithelioid mesothelioma is the most common histologic form of malignant mesothelioma. The name describes how the cancer cells look and organize under a microscope; it does not identify where the cancer began or how far it has spread.
Compared with sarcomatoid and biphasic mesothelioma, epithelioid tumors are generally associated with a more favorable prognosis and may be more likely to be considered for surgery in properly selected patients. Treatment still depends on tumor location, stage, lymph-node involvement, health and individual goals.
🧬 Epithelioid Mesothelioma Overview
Epithelioid is one of the three principal mesothelioma cell types. The others are sarcomatoid mesothelioma and biphasic mesothelioma, which contains both epithelioid and sarcomatoid components.
The National Cancer Institute’s professional treatment summary states that epithelioid tumors account for approximately 60% of mesothelioma diagnoses. Reported proportions may vary because studies include different tumor locations, patient populations and pathology criteria.
| Feature | Epithelioid Mesothelioma | Why It Matters |
|---|---|---|
| Histology | Epithelial-like malignant mesothelial cells | Helps classify the tumor and distinguish it from other cancers |
| Relative frequency | Most common principal cell type | Has the largest evidence base among mesothelioma histologies |
| Common locations | Pleura and peritoneum; rarer sites are possible | Location affects symptoms, staging and treatment |
| General outlook | Usually more favorable than nonepithelioid histology | Histology is only one prognostic factor |
| Surgical relevance | May support surgical evaluation in otherwise suitable patients | Resectability and overall fitness remain essential |
🔬 Cell Appearance, Patterns and Tumor Grade
Epithelioid cells are typically more cohesive than sarcomatoid cells and may appear cuboidal, oval or polygonal. Pathologists evaluate how the cells are arranged, how abnormal their nuclei appear, how actively they divide and whether tissue necrosis is present.
The report may describe tubulopapillary, trabecular, adenomatoid, solid or other architectural patterns. These terms help document tumor morphology, but they should not be interpreted as separate diseases or stand-alone treatment instructions.
| Pathology Feature | What the Pathologist Evaluates | Clinical Caution |
|---|---|---|
| Architecture | Tubular, papillary, trabecular, solid or other growth patterns | Pattern alone does not establish malignancy |
| Nuclear features | Cellular atypia, nuclear size and irregularity | Must be interpreted with the full specimen |
| Mitotic activity | How frequently tumor cells are dividing | Counting methods and significance depend on pathology standards |
| Necrosis | Areas of dead tumor tissue | May add prognostic information but is not used alone |
| Invasion | Tumor extending into fat, muscle or other tissue | Important for proving malignant behavior |
For diffuse pleural epithelioid mesothelioma, contemporary pathology reporting may include nuclear grade and an overall histologic grade. Higher-grade features generally suggest more aggressive biology. Grade and stage answer different questions: grade reflects microscopic appearance, while stage reflects anatomic spread.
🫁 Tumor Locations and Possible Symptoms
Epithelioid histology does not cause a unique symptom pattern. Symptoms primarily reflect where the tumor developed, how extensive it is and whether fluid has accumulated around the lungs, abdomen or another organ.
| Location | Possible Symptoms | Common Fluid Problem |
|---|---|---|
| Pleura around the lungs | Shortness of breath, chest or rib pain, cough, fatigue and unexplained weight loss | Pleural effusion |
| Peritoneum in the abdomen | Abdominal swelling or pain, early fullness, nausea, bowel changes and weight loss | Ascites |
| Pericardium around the heart | Breathlessness, chest discomfort, palpitations and fatigue | Pericardial effusion |
| Tunica vaginalis around a testicle | Scrotal swelling, a mass, heaviness or hydrocele | Hydrocele |
Pleural mesothelioma is the most common anatomic form. Peritoneal mesothelioma is the second most common and has different staging and surgical considerations. Symptoms cannot determine cell type; tissue examination is required.
Seek urgent medical care for severe breathing difficulty, fainting, rapidly worsening chest pain, severe abdominal pain, repeated vomiting, confusion or another sudden dangerous symptom.
🧪 Biopsy and Pathology Diagnosis
Imaging may reveal pleural thickening, masses, abdominal nodules or fluid, but it cannot reliably identify epithelioid histology. A tissue mesothelioma biopsy gives a pathologist the architecture and cells needed for diagnosis.
| Diagnostic Component | Purpose | Important Limitation |
|---|---|---|
| Microscopic examination | Identifies epithelioid architecture and cellular features | A small sample may not represent the whole tumor |
| Mesothelial immunostains | Support mesothelial differentiation | No single marker confirms every case |
| Carcinoma-exclusion markers | Help distinguish mesothelioma from lung or metastatic adenocarcinoma | The panel must match the clinical differential diagnosis |
| BAP1 or MTAP immunohistochemistry | Loss can support malignant mesothelial proliferation in appropriate settings | Retained expression does not rule out mesothelioma |
| CDKN2A testing | Deletion may provide evidence supporting malignancy | Not every tumor shows the alteration |
| Clinical and imaging correlation | Confirms that pathology fits the tumor’s site and behavior | Discordant findings may require more tissue or expert review |
Immunohistochemistry
Common positive mesothelial markers may include calretinin, WT1, D2-40 and cytokeratin 5/6. Pathologists also use markers intended to exclude adenocarcinoma and other tumors. The exact panel depends on the tumor site, appearance and suspected alternatives.
Epithelioid mesothelioma can resemble adenocarcinoma, reactive mesothelial proliferation and other malignancies. When the diagnosis is uncertain or a major operation is being considered, a mesothelioma second opinion from an experienced pathologist may be valuable.
Questions After an Epithelioid Mesothelioma Diagnosis?
Our team can help you locate information and understand possible legal options related to asbestos exposure.
Call 800.291.0963 Submit Your Case
Live chat is available 24/7/365.
📍 Staging and Disease Assessment
For diffuse pleural mesothelioma, the AJCC TNM system evaluates the primary tumor, regional lymph nodes and distant metastasis to assign stages I through IV. Imaging provides a clinical stage, while surgery can sometimes provide additional pathologic staging information.
Peritoneal mesothelioma does not use a universally adopted AJCC I–IV system equivalent to pleural staging. Specialists may assess the distribution of abdominal disease, calculate a Peritoneal Cancer Index, evaluate disease outside the abdomen and estimate whether complete cytoreduction appears achievable.
| Assessment | Question It Helps Answer | Why It Matters |
|---|---|---|
| CT, PET/CT or MRI | Where is disease visible, and what structures may be involved? | Guides staging, biopsy and treatment planning |
| Lymph-node evaluation | Has cancer reached regional nodes? | Nodal disease can affect surgery and prognosis |
| Histology and grade | What does the tumor look like microscopically? | Adds prognostic information beyond anatomy |
| Resectability review | Can visible disease be removed with acceptable risk? | Determines whether surgery deserves consideration |
| Heart, lung and organ testing | Can the patient safely tolerate the proposed therapy? | Balances potential benefit against harm |
The site’s mesothelioma staging guide explains pleural TNM terminology. A favorable cell type does not cancel the importance of stage, nodal disease or distant spread.
💊 Epithelioid Mesothelioma Treatment Options
There is no single standard plan for every epithelioid tumor. A multidisciplinary team may include medical oncology, thoracic or surgical oncology, radiation oncology, pulmonology, pathology, radiology, supportive care and other specialists.
| Treatment | How It May Be Used | Key Considerations |
|---|---|---|
| Surgery | May be part of treatment for selected localized or resectable disease | Site, stage, nodal status, completeness of removal, organ function and operative risk |
| Chemotherapy | Pemetrexed with a platinum drug is an established systemic option in pleural disease | Kidney function, hearing, blood counts, performance status and prescribed vitamin support |
| Immunotherapy | Approved regimens are available for specified unresectable pleural mesothelioma settings | Histology, autoimmune conditions, organ function, side effects and current labeling |
| Radiation therapy | May address a defined tumor area, pain or selected multimodality goals | Nearby organs, treatment field, prior radiation and expected benefit |
| Fluid procedures | May relieve pleural effusion or ascites | Fluid can recur; the plan should address symptoms and underlying disease |
| Clinical trial | May offer access to an investigational strategy | Eligibility, uncertain benefit, additional testing and travel burden |
Surgery Depends on More Than Histology
Epithelioid histology may support consideration of surgery for mesothelioma, but it does not automatically make a patient eligible. Pleural operations can include pleurectomy/decortication and, less commonly, extrapleural pneumonectomy. Selected peritoneal patients may be evaluated for cytoreductive surgery with HIPEC.
Major surgery can cause serious complications and should be evaluated at an experienced center. Patients should ask what operation is proposed, whether complete macroscopic tumor removal appears possible, what nonsurgical alternatives exist and how the team measures benefit and risk.
Systemic Therapy Is Location-Specific
Modern treatment options for unresectable pleural mesothelioma include chemotherapy and immune-checkpoint-based regimens. An approval or trial conducted in pleural disease should not automatically be applied to peritoneal, pericardial or testicular mesothelioma. Review current mesothelioma treatments with the treating oncologist.
📈 Prognosis and Factors That Affect Outcomes
Epithelioid histology is generally associated with a better prognosis than sarcomatoid or biphasic histology. This is a population-level pattern, not a personalized survival prediction. Some epithelioid tumors progress quickly, while some patients respond to treatment for a meaningful period.
| Prognostic Factor | Why It Can Matter |
|---|---|
| Tumor location | Pleural and peritoneal disease use different assessment and treatment approaches |
| Stage or distribution | More limited disease may allow additional local treatment options |
| Lymph-node or distant spread | Spread can reduce the role of surgery and indicates broader disease |
| Histologic grade and pattern | Microscopic features may add information within epithelioid disease |
| Completeness of surgery | Residual tumor burden can affect outcomes in selected surgical patients |
| Performance status and organ function | Influence treatment safety, intensity and tolerance |
| Response to therapy | Imaging, symptoms and clinical status show how disease is behaving over time |
Online survival figures may combine different stages, tumor sites, treatment eras and patient-selection criteria. Surgical studies often include healthier patients with more favorable disease, so their results should not be applied to everyone. Read the broader mesothelioma prognosis guide and ask the specialist which evidence most closely resembles the individual case.
📋 Next Steps After an Epithelioid Diagnosis
- Confirm the pathology. Ask whether adequate tissue was obtained, which stains were used and whether grade was reported.
- Confirm the primary location. Pleural and peritoneal disease require different staging and treatment discussions.
- Complete disease assessment. Review imaging, lymph-node findings and relevant organ-function testing.
- Request multidisciplinary review. Compare surgery, systemic therapy, radiation, symptom management and clinical-trial options.
- Clarify treatment goals. Ask whether the goal is tumor control, symptom relief, longer survival, preserving function or a combination.
- Keep complete records. Preserve pathology reports, imaging discs, procedure notes, medication lists and exposure history.
Authoritative Medical Sources
- National Cancer Institute: Malignant Mesothelioma Treatment (PDQ), Health Professional Version
- National Cancer Institute: Mesothelioma
- National Cancer Institute: Tumor Grade
- College of American Pathologists: Pleural Mesothelioma Resection Protocol
- Centers for Disease Control and Prevention: Mesothelioma Basics
- ClinicalTrials.gov: Mesothelioma Studies
❓ Frequently Asked Questions
What is epithelioid mesothelioma?
It is malignant mesothelioma composed of epithelial-like tumor cells. The diagnosis describes histology rather than tumor location or stage.
Is epithelioid mesothelioma the most common cell type?
Yes. The National Cancer Institute’s professional summary states that epithelioid tumors account for approximately 60% of mesothelioma diagnoses, although estimates vary among studies.
Is epithelioid mesothelioma less aggressive?
It is generally associated with a more favorable outlook than sarcomatoid or biphasic disease. Individual tumors still vary in grade, stage, growth and treatment response.
Can imaging confirm epithelioid histology?
No. Imaging can show tumor location and extent but cannot reliably determine cell type. A tissue biopsy and pathology examination are required.
Can epithelioid mesothelioma be confused with lung cancer?
Yes. Pleural epithelioid mesothelioma can resemble lung adenocarcinoma or metastatic cancer. Pathologists use tumor architecture, invasion and immunohistochemical panels to distinguish them.
Does epithelioid histology make surgery possible?
It may support surgical evaluation, but histology alone is not enough. Location, stage, lymph nodes, resectability, organ function, overall health and operative risk must also be assessed.
What treatments are used for epithelioid mesothelioma?
Depending on tumor location and extent, treatment may include surgery, chemotherapy, immunotherapy, radiation, fluid-management procedures, supportive care or a clinical trial.
Should I request a pathology second opinion?
A specialist review is reasonable when tissue is limited, findings conflict, the diagnosis is unusual or a major treatment decision depends on accurate histology and grade.
Talk With Our Mesothelioma Support Team
If you or a loved one has been diagnosed with epithelioid mesothelioma, we can help you find information and understand possible legal options related to asbestos exposure. There is no obligation.
Call 800.291.0963 Submit Your Case
Live chat is available 24/7/365.
Medical and legal disclaimer: This page provides general educational information and is not a substitute for advice from a licensed physician or attorney. Diagnosis and treatment decisions must be made with qualified health professionals. Case eligibility and legal rights depend on individual facts and applicable law; contacting us does not create an attorney-client relationship